statement
IMVT-1402 value was calculated at approximately 3.7 trillion won.
A statement by 하나증권 제약/바이오 김선아. Statements are as reported by the cited publishers — not verified by DecisionGateway.
IMVT-1402 가치 약 3.7조원으로 산정
Discussion
Related claims
This is the first case clinically demonstrating the strategic advantage IMVT-1402 has over Batoclimab.하나증권 제약/바이오 김선아 · statementFollowing the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statementIMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.report author · statementImmunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.report author · statementIMVT-1402 is designed so its binding epitope does not compete with albumin, allowing high-dose continuous administration without hypercholesterolemia concerns, whereas Batoclimab requires dose reduction after several weeks.하나증권 제약/바이오 김선아 · statementThe total consideration is approximately 19.79 亿元.周大福创建公告 · statement